Dr. Michael Patrick Boyle M.D.

Recommended Articles

• University Dance Promotes Cystic Fibrosis Awareness

  Cystic fibrosis is considered incurable, and is a daily struggle for all of those who have it. Constant research is being poured into finding better treatment, and potentially even a cure, but Rowan's Public Relations Student Society of America (PRSSA) is putting their own spin (literally) on...

• All About Bronchopneumonia

  Pneumonia is an infection of the lung tissue, which can be caused by bacteria, viruses, and fungi. There are two types of pneumonia: lobar pneumonia and bronchopneumonia. Lobar pneumonia is when an entire lobe or more than one lobe of the lung gets involved. Bronchopneumonia happens when the bronchi...

• What Are the Signs and Symptoms of AIDS?

  Acquired immunodeficiency syndrome, or AIDS, is a serious secondary immunodeficiency disorder. AIDS is caused by human immunodeficiency virus (HIV). There is progressive destruction of cell-mediated (T cell) immunity. Also, both conditions are characterized by subsequent effects on humoral immunity...

• What Are the Signs and Symptoms of Lupus?

  It is very hard to diagnose lupus. Since two individuals can have different signs of lupus, doctors have a hard time diagnosing it and treating it effectively. To diagnose lupus, it can take a long time, which can be distracting to both the doctor and the affected person. The symptoms of lupus can...

• Cystic Fibrosis: FDA Extends Use of Relizorb to Children

  The ability to gain and maintain a healthy weight for patients who suffer from cystic fibrosis can be a challenge. Many children with the condition suffer from failure to thrive. The disorder has the tendency to cause a blockage in digestion that prevents necessary fats from being absorbed. Proper...

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...